Cooperation in Development Sample Clauses

Cooperation in Development. The Parties mutually acknowledge that, subject to other provisions of this Agreement, Licensor, Licensee and Parent shall closely collaborate (as the Parties may reasonably agree) in the development and commercialization of Product on a global basis. In furtherance of such collaboration, the Parties agree to share all non-clinical and clinical data, manufacturing, process and formulation data and any other information necessary for the development of the Products, which data shall constitute Confidential Information and be subject to the terms and conditions of Section 8, and to provide each other the right to use and make reference to such data and information in each Party’s respective efforts to develop Products, in the case of Licensee, within the Field in the Territory, or in the case of Licensor, outside the Territory or outside the Field in the Territory. INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.
Sample 1
AutoNDA by SimpleDocs
Cooperation in Development. The Parties acknowledge that, from time to time, Astellas may, or may request XenoPort to, conduct activities outside the Territory (for example, to conduct certain clinical trials in the United States on Japanese subjects) for use in obtaining Marketing Approval of the Product in the Territory. Any activities outside the Territory conducted or requested by Astellas pursuant to this Section 4.7 shall be subject to the consent of XenoPort, which consent shall not be unreasonably withheld or delayed. Subject to such consent, XenoPort shall cooperate as mutually agreed to perform such activities, the cost of which shall be reimbursed by Astellas (including without limitation payment of the supply price of the clinical supplies used in such activities, in accordance with any supply agreement between the Parties then in effect). * CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
Sample 1
Cooperation in Development. The Parties acknowledge that, from time to time, Astellas may or, may request XenoPort to, conduct activities outside the Territory (for example, to conduct certain clinical trials in the United States on Japanese subjects) for use in * Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. obtaining Marketing Approval of the Product in the Territory. Any activities outside the Territory conducted or requested by Astellas pursuant to this Section 4.7 shall be subject to the consent of XenoPort, which consent shall not be unreasonably withheld or delayed. Subject to such consent, XenoPort shall cooperate as mutually agreed to perform such activities, the cost of which shall be reimbursed by Astellas (including without limitation payment of the supply price of the clinical supplies used in such activities, in accordance with the Supply Agreement).
Sample 1
Cooperation in Development. Each party (each, a "Cooperating Party") -------------------------- shall cooperate with the other party in connection with (1) all land use activities required to proceed with the development of either the Real Property or the Retained Property and (2) accomplishing the Great Oaks Extension Project, so long as such cooperation shall be at no expense to nor to the detriment of the Cooperating Party. The covenants contained in this section 6.8 are separate from and in addition to the obligations set forth in section 6.5 hereof or elsewhere contained herein.
Sample 1
Cooperation in Development. The Parties mutually acknowledge that, subject to other provisions of this Agreement, Licensor and Licensee shall closely collaborate (as the Parties may reasonably agree) in the development and commercialization of Licensed Product on global basis.
Sample 1
Cooperation in Development. IC shall use its commercially reasonable efforts to cooperate with FRTI as FRTI works to fulfill its obligations under this Agreement. Such cooperation shall include, without limitation, consultation with the personnel of IC who are the most knowledgeable about the particular issue at hand, performing the obligations of IC under this Agreement in a timely manner, providing content and IC Intellectual Property in the form and format reasonably requested by FRTI, and undertaking such other actions that are not enumerated in this Agreement but are reasonably related to the purposes of this Agreement or may be reasonably expected to be rendered by IC during the course of this Agreement.
Sample 1
Cooperation in Development. The parties agree to work co-operatively for the development and implementation of SPEAR.
Sample 1
AutoNDA by SimpleDocs

Related to Cooperation in Development

  • Independent Development Receiving Party may currently or in the future be developing information internally, or receiving information internally, or receiving information from other parties that may be similar to the Disclosing Party's Confidential Information. Accordingly, nothing in this Agreement will be construed as a representation or inference that Receiving Party will not develop or have developed products or services, that, without violation of this Agreement, might compete with the products or systems contemplated by the Disclosing Party's Confidential Information.

  • Joint Development If joint development is involved, the Recipient agrees to follow the latest edition of FTA Circular 7050.1, “Federal Transit Administration Guidance on Joint Development.”

  • Clinical Development Licensee will have sole responsibility for and sole decision making over the clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial.

  • Information Systems Acquisition Development and Maintenance Security of System Files. To protect City Information Processing Systems and system files containing information, Service Provider will ensure that access to source code is restricted to authorized users whose specific job function necessitates such access.

  • Adverse Developments Promptly after the Lessee acquires knowledge thereof, written notice of:

  • Status as Business Development Company The Borrower is an “investment company” that has elected to be regulated as a “business development company” within the meaning of the Investment Company Act and qualifies as a RIC.

  • Research and Development (i) Advice and assistance in relation to research and development of Party B;

  • Development 3.3 Within twenty (20) Working Days after the Commencement Date and in accordance with paragraphs 3.10 to 3.12 (Amendment and Revision), the Contractor will prepare and deliver to the Authority for approval the full and final Security Plan which will be based on the draft Security Plan set out in Appendix B.

  • Condominiums/Planned Unit Developments If the Mortgaged Property is a condominium unit or a planned unit development (other than a de minimis planned unit development) such condominium or planned unit development project such Mortgage Loan was originated in accordance with, and the Mortgaged Property meets the guidelines set forth in the Originator's Underwriting Guidelines;

  • Proprietary Information and Developments 9.1 The Consultant will not at any time, whether during or after the termination of this Agreement for any reason, reveal to any person or entity any of the trade secrets or confidential information concerning the organization, business or finances of the Company or of any third party which the Company is under an obligation to keep confidential, except as may be required in the ordinary course of performing the Consultant Services to the Company, and the Consultant shall keep secret such trade secrets and confidential information and shall not use or attempt to use any such secrets or information in any manner which is designed to injure or cause loss to the Company. Trade secrets or confidential information shall include, but not be limited to, the Company's financial statements and projections, expansion proposals, property acquisition opportunities and business relationships with banks, lenders and other parties not otherwise publicly available.

Time is Money Join Law Insider Premium to draft better contracts faster.